A Ten-Year Real-Life Experience with Pazopanib in Uterine Leyomiosarcoma in Two High-Specialized Centers in Italy: Effectiveness and Safety
by
,
Mara Mantiero
1,*
,
Marta Bini
2,
Maggie Polignano
1,
Luca Porcu
3,
Roberta Sanfilippo
2,
Chiara Fabbroni
2,
Gabriella Parma
4,
Mariateresa Lapresa
4,
Carmelo Calidona
4,5,
Cecilia Silvestri
2,
Andrea Franza
2,
Francesco Raspagliesi
1,
Nicoletta Colombo
4,6 and
Monika Ducceschi
1 1
Department of Gynecologic Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy
2
Department of Medical Oncology, National Cancer Institute of Milan, Via Venezian 1, 20133 Milan, Italy
3
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
4
Gynecologic Oncology Division, European Institute of Oncology, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy
5
Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Piazzale Aristide Stefani 1, 37126 Verona, Italy
6
University of Milan-Bicocca, Piazza dell’Ateneo Nuovo 1, 20126 Milan, Italy
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(1), 192; https://doi.org/10.3390/cancers16010192
Submission received: 22 November 2023
/
Revised: 20 December 2023
/
Accepted: 25 December 2023
/
Published: 30 December 2023
(This article belongs to the Special Issue Advances in the Diagnosis and Management of Uterine Sarcomas)
Simple Summary
Pazopanib is an oral drug for metastatic pretreated uterine leiomyosarcoma that received approval in 2012, but poor data have been reported on its activity in real life since the disease is very rare. Uterine leiomyosarcoma has a poor objective response rate to other agents. We assessed the effectiveness and safety of pazopanib in everyday clinical practice, showing its activity and tolerability in patients.
Abstract
Background: Uterine leiomyosarcoma (uLMS) is characterized by aggressive behavior associated with a high risk of relapse and mortality. Several therapeutic agents have been employed in the treatment of metastatic disease, with a poor objective response rate. Pazopanib, approved in 2012, is a multi-targeted, orally active small molecule that exerts its effects by inhibiting several tyrosine kinases. To date, poor research on real-life data has been conducted. We aimed to assess the effectiveness and safety of the drug in everyday clinical practice. Methods: We present results of multicenter retrospective data on 38 patients with heavily pretreated metastatic uLMS who underwent oral pazopanib during their therapeutic journey. Results: At a median follow-up of 8.6 months, the disease control rate was 55.2%, with 17% partial responses and 15 patients (39.5%) with stable disease. At a median follow-up of 8.6 months, median progression-free survival was 4 months, and median overall survival was 19.8 months. The most common grade 3 adverse events (AEs) drug-related were hepatic toxicities, diarrhea, hypertension, nausea, and vomiting (all of them with an incidence of 5% considering the whole study cohort). No grade 4 AEs occurred. Conclusions: Pazopanib in everyday clinical practice is safe and shows a good disease control rate with prolonged survival.
Keywords:
uterine leyomiosarcoma; pazopanib; effectiveness; safety; survival
